Journal
CANCER CELL
Volume 3, Issue 3, Pages 285-296Publisher
CELL PRESS
DOI: 10.1016/S1535-6108(03)00050-3
Keywords
-
Categories
Funding
- NCI NIH HHS [K01 CA94223, R01 CA097061, 1R01CA97061-01, 1K08CA96755-01, K08 CA096755-01] Funding Source: Medline
Ask authors/readers for more resources
We used synthetic lethal high-throughput screening to interrogate 23,550 compounds for their ability to kill engineered tumorigenic cells but not their isogenic normal cell counterparts. We identified known and novel compounds with genotype-selective activity, including doxorubicin, daunorubicin, mitoxantrone, camptothecin, sangivamycin, echinomycin, bouvardin, NSC146109, and a novel compound that we named erastin. These compounds have increased activity in the presence of hTERT, the SV40 large and small T oncoproteins, the human papillomavirus type 16 (HPV) E6 and E7 oncoproteins, and oncogenic HRAS. We found that overexpressing hTERT and either E7 or LT increased expression of topoisomerase 2alpha and that overexpressing RAS(V12) and ST both increased expression of topoisomerase I and sensitized cells to a nonapoptotic cell death process initiated by erastin.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available